Vor BiopharmaVOR
About: Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Employees: 168
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
10.19% less ownership
Funds ownership: 80.14% [Q2] → 69.95% (-10.19%) [Q3]
24% less funds holding
Funds holding: 71 [Q2] → 54 (-17) [Q3]
39% less capital invested
Capital invested by funds: $54.7M [Q2] → $33.5M (-$21.2M) [Q3]
58% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 19
62% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 26
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth 32% 1-year accuracy 62 / 191 met price target | 1,067%upside $17.50 | Buy Reiterated | 10 Dec 2024 |
JMP Securities Silvan Tuerkcan 29% 1-year accuracy 16 / 56 met price target | 700%upside $12 | Market Outperform Reiterated | 10 Dec 2024 |
Baird Jack Allen 33% 1-year accuracy 3 / 9 met price target | 833%upside $14 | Outperform Maintained | 8 Nov 2024 |
Financial journalist opinion
Based on 3 articles about VOR published over the past 30 days









